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on behalf of the EXCITE ISR InvestigatorsABSTRACTOBJECTIVES The purpose of this study was to evaluate the safety and efﬁcacy of excimer laser atherectomy (ELA) with
adjunctive percutaneous transluminal angioplasty (PTA) versus PTA alone for treating patients with chronic peripheral
artery disease with femoropopliteal bare nitinol in-stent restenosis (ISR).
BACKGROUND Femoropopliteal stenting has shown superiority to PTA for lifestyle-limiting claudication and critical
limb ischemia, although treating post-stenting artery reobstruction, or ISR, remains challenging.
METHODS The multicenter, prospective, randomized, controlled EXCITE ISR (EXCImer Laser Randomized Controlled
Study for Treatment of FemoropopliTEal In-Stent Restenosis) trial was conducted across 40 U.S. centers. Patients with
Rutherford Class 1 to 4 and lesions of target lesion length $4 cm, vessel diameter 5 to 7 mm were enrolled and randomly
divided into ELA þ PTA and PTA groups by a 2:1 ratio. The primary efﬁcacy endpoint was target lesion revascularization
(TLR) at 6-month follow up. The primary safety endpoint was major adverse event (death, amputation, or TLR) at 30 days
post-procedure.
RESULTS Study enrollment was stopped at 250 patients due to early efﬁcacy demonstrated at a prospectively-speciﬁed
interim analysis. A total of 169 ELA þ PTA subjects (62.7% male; mean age 68.5  9.8 years) and 81 PTA patients (61.7%
male; mean age 67.8  10.3 years) were enrolled. Mean lesion length was 19.6  12.0 cm versus 19.3  11.9 cm, and
30.5% versus 36.8% of patients exhibited total occlusion. ELA þ PTA subjects demonstrated superior procedural success
(93.5% vs. 82.7%; p ¼ 0.01) with signiﬁcantly fewer procedural complications. ELA þ PTA and PTA subject 6-month
freedom from TLR was 73.5% versus 51.8% (p < 0.005), and 30-day major adverse event rates were 5.8% versus 20.5%
(p < 0.001), respectively. ELA þ PTA was associated with a 52% reduction in TLR (hazard ratio: 0.48; 95% conﬁdence
interval: 0.31 to 0.74).
CONCLUSIONS The EXCITE ISR trial is the ﬁrst large, prospective, randomized study to demonstrate superiority
of ELA þ PTA versus PTA alone for treating femoropopliteal ISR. (Randomized Study of Laser and Balloon Angioplasty
Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis [EXCITE ISR]; NCT01330628) (J Am Coll Cardiol Intv
2015;8:92–101) © 2015 by the American College of Cardiology Foundation.
AB BR EV I A T I O N S
AND ACRONYM S
DS = diameter stenosis
DUS = duplex ultrasound
ISR = in-stent restenosis
MAE = major adverse event
PAD = peripheral artery
disease
PTA = percutaneous
transluminal angioplasty
TLR = target lesion
revascularization
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93A dvancements in nitinol stents have revo-lutionized femoropopliteal treatment inpatients with chronic peripheral arterial dis-
ease (PAD). The effectiveness of these methods is, in
part, due to the ability of nitinol stents to effectively
address historically problematic issues with conven-
tional percutaneous transluminal angioplasty (PTA),
including well-documented limitations such as
elastic recoil, residual stenosis, and ﬂow-limiting
dissection (1–7). Despite notable improvements in
stenting devices and techniques in the past decade,
up to one-half of all patients that receive femoropo-
pliteal stents will require secondary interventions
(>115,000 procedures annually) due to in-stent reste-
nosis (ISR), a form of arterial recurrent obstruction
particularly common in long and complex lesions
(8,9). As a result, there remains an unmet need for
more effective ways to treat ISR.
Conventional treatment strategies for ISR include
PTA with or without repeat stenting (bare-metal
stents, stent grafts, or drug-eluting stents), drug-
eluting or cutting balloon angioplasty, cryoplasty,
and directional or laser atherectomy (10–18). The re-
cent proliferation of treatment options has, however,
complicated clinical treatment of ISR, resulting in a
variety of reports with highly variable results that
may be related to disparities in lesion crossing and
repeat restenosis risk. Effectiveness of ISR treatments
can be gauged by examining procedural success, com-
plications, and post-treatment stenosis as well as
the occurrence of major adverse events (MAEs) and
target lesion revascularization (TLR) in the months
following surgery.
Excimer laser atherectomy (ELA) allows for pho-
toablation of residual hyperplasic tissues. A pro-
spective, multicenter study of 90 patients with ISR
of nitinol stents implanted in the femoropopliteal
arteries conducted by Schmidt et al. (16) in 2014
demonstrated that ELA combined with adjunctive
PTA resulted in 97% procedural success, 7% residual
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suggest that ELA with adjunctive PTA may be
more efﬁcacious than PTA alone for treatment
of femoropopliteal ISR, although no prior
large, randomized studies have been
completed. The current prospective, random-
ized, controlled trial was conducted for U.S.
Food and Drug Administration submission to
evaluate the safety and efﬁcacy of ELA with
adjunctive PTA versus PTA alone for the
treatment of femoropopliteal ISR.
METHODSSTUDY DESIGN. The EXCITE ISR (EXCImer Laser
Randomized Controlled Study for Treatment of Fem-
oropopliTEal In-Stent Restenosis) trial is a mul-
ticenter, prospective, randomized, controlled trial
conducted across 40 centers in the United States with
enrollment from June 2011 to February 2014. The
expected enrollment was up to 318 chronic PAD pa-
tients with successful intraluminal guidewire crossing
and 35 chronic PAD patients with unsuccessful intra-
luminal guidewire crossing, reported as a separate
total occlusion registry component (not included
in this report). The trial was conducted under an
Investigational Device Exemption approved by the
U.S. Food and Drug Administration. The study was
approved by the institutional review board of each
institution, and written informed consent was ob-
tained from each patient prior to enrollment. This
clinical trial was registered at www.clinicaltrials.gov
(NCT01330628). A full list of the EXCITE ISR inves-
tigators can be found in the Online Appendix.
PATIENT SELECTION AND RANDOMIZATION. The study
included patients age 18 to 85 years, with Rutherford
Class 1 to 4 PAD, and with resting or abnormal exercise
ankle-brachial index <0.9 in the target limb. Angio-
graphic inclusion criteria included signiﬁcant ISR
$50% diameter stenosis (DS) by visual assessments of Northwest Indiana, Munster, Indiana; zDeborah
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94within previously deployed femoropopliteal stent(s),
target lesion length $4 cm, and reference vessel
diameter between 5 and 7 mm. A minimum of 1 patent
tibial vessel or peroneal artery to the foot con-
taining <50% DS by visual estimate that did
not require intervention prior to the 1-month follow-
up was required. Additional anatomic inclusion
criteria included: patent inﬂow vessel prior to study
enrollment with or without treatment and peristent
lesion not to exceed 3 cm. Exclusion criteria included
pregnancy, acute limb ischemia, life expectancy
<12 months, cerebrovascular accidents or myocardial
infarction within 60 days prior to procedure, con-
traindications or allergies that could affect the pro-
cedure, uncontrolled hypercoagulability, systemic
infection in target limb, previous treatment to
the target vessel within 3 months prior to study
procedure, serum creatinine $2.5 mg/dl unless
dialysis-dependent, aneurysm within target lesion,FIGURE 1 Study Diagram
A total of 250 patients were randomized 2:1 to excimer laser atherectom
(ELAþ PTA group) or PTA alone with available follow-up. *Exit due to tar
†Includes patients with follow-up visit or prior major adverse event. ‡Indrug-eluting stents or covered stents in the target
lesion, planned or predicted cardiac surgery or in-
terventions prior to completion of 30-day follow-up,
or grade 4/5 stent fracture affecting target stent or
proximal to the target stent.
Patients meeting the criteria were consecutively
enrolled and randomly allocated into 2 groups,
ELA with adjunctive PTA (ELA þ PTA group) or
PTA alone (PTA group) using a 2:1 allocation blocked
by site, using random block sizes of 3 and 6.
PROCEDURE. Subjects were admitted and prepared
according to the standard clinical practice at each
participating institution, including necessary admin-
istrations of oral antiplatelet (antithrombotic) ther-
apy. Pre-procedural and periprocedural diagnostic
and guidance imaging was performed to determine
eligibility. Vessel calcium was graded angiographic-
ally using the following criteria: none/mild ¼ noy (ELA) with adjunctive percutaneous transluminal angioplasty (PTA)
get lesion revascularization (TLR), amputation, death, or discontinued.
cludes patients with follow-up visit or prior TLR.
TABLE 2 Baseline Lesion Characteristics
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95radio-opacities; moderate ¼ radio-opacities appear
unilaterally on arterial wall or <1 cm (length) prior to
contrast injection or digital subtraction angiography;
and severe ¼ radio-opacities appear bilaterally on
arterial wall and extend >1 cm (length) prior to con-
trast injection or digital subtraction angiography.
Stent fracture was assessed via straight-leg x-ray
or ﬂuoroscopy in 2 orthogonal views prior to inter-
vention. Stent fractures were graded by severity score
according to published criteria (19).
Intraluminal crossing with a guidewire was per-
formed from a contralateral crossover approach or via
antegrade femoral access utilizing standard endo-
vascular techniques. Distal embolic protection was
employed according to operator discretion. For
ELA þ PTA subjects, a pilot channel was created
(if necessary) using a Turbo Elite laser catheter
(Spectranetics Corp., Colorado Springs, Colorado). A
Turbo Tandem laser catheter (Spectranetics Corp.)
was then used to achieve maximum debulking,
generally applied using 4 quadrant passes and start-
ing parameters: Turbo Elite 45 Hz repetition rate
and 25 mJ/mm2 ﬂuence and Turbo Tandem 60 Hz
repetition rate and 40 mJ/mm2 ﬂuence. PTA was
performed between nominal and rated burst pres-
sures over the course of 2 to 5 min. The use of spe-
cialty balloons or other atherectomy devices was not
permitted.TABLE 1 Baseline Patient Characteristics
ELA þ PTA
(n ¼ 169)
PTA
(n ¼ 81) p Value
Demographics
Male 62.7 61.7 0.89
Age, yrs 68.5  9.8 67.8  10.3 0.60
BMI, kg/m2 28.3  5.4 28.1  4.9 0.86
Medical history
Hyperlipidemia 96.4 95.0 0.73
Hypertension 95.8 93.8 0.53
Smoking history 85.0 91.3 0.23
CAD 64.3 68.8 0.57
Diabetes 47.0 47.5 1.00
Previous ISR in treated leg 32.7 30.0 0.77
CLI 16.0 12.3 0.57
CVA 10.7 6.3 0.35
ABI 0.6  0.2 0.7  0.2 0.33
Medications
Aspirin 91.1 88.9 0.65
Statin 81.7 86.4 0.37
Clopidogrel 81.7 81.5 1.00
Values are % or mean  SD.
ABI ¼ ankle brachial index; BMI ¼ body mass index; CAD ¼ coronary artery
disease; CLI ¼ critical limb ischemia; CVA ¼ cerebrovascular accident; ELA ¼
excimer laser atherectomy; ISR ¼ in-stent restenosis; PTA ¼ percutaneous trans-
luminal angioplasty.FOLLOW-UP. Patients underwent clinical follow-up
at discharge and clinical follow-up with duplex ul-
trasound (DUS) at 30 days, 6 months, and 12 months.
Stent integrity was investigated with straight-leg
ﬂat plate x-rays or ﬂuoroscopy at 6 and 12 months.
EFFICACY OUTCOMES. The primary efﬁcacy endpoint
was freedom from TLR through 6-month follow-up.
Secondary endpoints included acute procedural suc-
cess, TLR through 12-month follow-up, DUS-assessed
patency, ankle-brachial index, change in Rutherford
score, and stent integrity.
Procedural success was deﬁned as #30% residual
diameter stenosis following assigned treatment with-
out provisional or bailout procedures. Patency was
deﬁned as <50% DS as assessed by DUS in the absence
of TLR, amputation, and/or surgical bypass. Peak
systolic velocity ratio #2.5 was used as the patency
threshold. Clinically-driven TLR was deﬁned as a
reintervention performed for >50% diameter stenosis
or in the target lesion after documentation of recur-
rent clinical symptoms following the index procedure
or bailout stenting during the index procedure.
SAFETY OUTCOMES. The primary safety endpoint
was MAE occurrence through 30-day follow-up
(37 days post-procedure) deﬁned as all-cause death,ELA þ PTA
(n ¼ 169)
PTA
(n ¼ 81) p Value
Lesion length, cm 19.6  120 19.3  119 0.85
>10 72.7 76.3
>20 43.5 40.8
>30 21.4 21.1
>40 7.1 6.6
Stent length, cm 21.7  112 20.5  106 0.43
Reference vessel diameter, mm 4.6  0.8 4.6  0.8 0.99
% diameter stenosis 81.7  16.4 83.5  16.9 0.42
Total occlusion 30.5 36.8 0.37
TASC II C/D lesion (7) 59.9 56.9 0.77
#1 runoff vessel 38.1 24.7 0.10
Stent fracture (19) 0.08
None 85.8 95.8
Type 1 or 2 11.4 4.2
Type 3, 4, or 5 2.8 0
Calciﬁcation 0.002
None/mild 72.9 90.9
Moderate 23.2 6.5
Severe 3.9 2.6
Lesion location 0.93
SFA 78.7 76.6
SFA/popliteal 16.1 18.2
Popliteal 5.2 5.2
Values are mean  SD or %.
SFA ¼ superﬁcial femoral artery; TASC ¼ TransAtlantic Inter-Society Consensus;
other abbreviations as in Table 1.
FIGURE 2 Freedom
Kaplan-Meier surviva
shown at the bottom
TABLE 3 Procedural Outcomes
ELA þ PTA
(n ¼ 169)
PTA
(n ¼ 81) p Value
Turbo Elite used 79.9 — —
Distal protection 40.2 30.9 0.16
% diameter stenosis* 23.9  9.3 25.5  10.9 0.24
Residual stenosis >30% 4.7 13.6 0.02
Dissection grade
Any 7.7 17.2 0.03
$Grade C 2.4 7.4 0.08
Embolism 8.3 4.9 0.44
Bailout stenting 4.1 11.1 0.05
Procedural TLR 5.3 16.0 0.008
Values are % or mean  SD. *Post-assigned treatment.
TLR ¼ target lesion revascularization; other abbreviations as in Table 1.
Dippel et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 , 2 0 1 5
Excimer Lasers for Femoropopliteal ISR J A N U A R Y 2 0 1 5 : 9 2 – 1 0 1
96unplanned major amputation, or TLR. All adverse
events (AEs), regardless of severity or relationship to
the procedure, were recorded. AEs were classiﬁed by
seriousness, severity, and relationship to procedure.
DATA QUALITY. Data were recorded on case report
forms using an electronic data capture. Trial over-
sight and adverse event adjudication was provided
by a Data Safety Monitoring Board. Independent
core laboratories analyzed angiographic (Synvacore,
Springﬁeld, Illinois) and DUS studies (VasCore, Bos-
ton, Massachusetts). Patients and readers at the DUS
and angiographic imaging core laboratories were
blinded to treatment assignment. Data management
and monitoring was conducted by an independentFrom TLR Through 1 Year
l curve up to 1 year is shown for TLR. Number of subjects at risk is
of the graph (p < 0.003). Abbreviations as in Figure 1.contract research organization (Medpace, Cincinnati,
Ohio).
SAMPLE SIZE. A maximum sample size of 318 pa-
tients was determined to be required for this study,
assuming 1-sided a ¼ 0.025, b ¼ 80%, assumed 70%
and 53% freedom from TLR at 6 months in the
ELA þ PTA and PTA groups, respectively (16,20), and
10% attrition. A Bayesian hierarchical model was
employed to prospectively assess results at 200, 250,
and 300 patients, with potential early termination
prior to enrolling the maximum subject population
if the primary endpoint was achieved with sufﬁcient
statistical power (prospective stopping rules).
STATISTICAL ANALYSIS. Continuous variables were
summarized as mean  SD, and categorical variables
were reported as counts and percentages. Between-
group comparisons were performed using the
2-sample t test for continuous variables and Fisher
exact test for categorical variables. Primary efﬁcacy
and safety endpoints were evaluated using the chi-
square test. Freedom from primary patency, TLR,
survival, and amputation were analyzed using the
product-limit Kaplan-Meier and the Cox propor-
tional hazards regression model. A stepwise back-
ward elimination technique was used to determine
independent predictors of target lesion revasculari-
zation. Variables were entered into the model at
p values <0.10, and stepwise backward elimination
multivariate analysis was conducted. A p value <0.05
was considered statistically signiﬁcant. Cox propor-
tional hazards models were used to estimate the
hazard ratio for the randomized comparison in sub-
groups for dichotomous baseline covariates or at a
speciﬁed level for continuous baseline covariates.
The Cox proportional hazards models included all
patients with independent variables at baseline co-
variate, the randomized group, and the interaction
term between baseline covariate and randomized
group. Statistical analysis was completed using SAS
version 9.4 (SAS Institute, Inc., Cary, North Carolina).
RESULTS
PATIENT ENROLLMENT. A total of 250 subjects were
randomized to ELA þ PTA (n ¼ 169) or PTA (n ¼ 81).
Seven patients with total occlusions uncrossable by
guidewire were enrolled in a separate registry. Per
the prospective Bayesian hierarchical model, assess-
ments were performed when enrollment reached 200
and 250 patients. As a result, the study stopping
criteria were met when the analysis was complete
for the initial 250 subjects demonstrating early suc-
cess for the primary safety and efﬁcacy endpoints.
FIGURE 3 Freedom From TLR Through 1 Year Without Bailout Stenting
Kaplan-Meier survival curve up to 1 year is shown for TLR. Number of subjects at risk
is shown at the bottom of the graph (p < 0.05). Abbreviations as in Figure 1.
FIGURE 4 Primary Patency Through 1 Year
Kaplan-Meier survival curve up to 1 year is shown for primary patency. Loss of primary
patency was deﬁned as occurrence of any of the following: TLR, target limb amputation,
target limb surgical bypass, or duplex ultrasound peak systolic velocity ratio #2.5. Number
of subjects at risk is shown at the bottom of the graph (p < 0.005). Abbreviations as in
Figure 1.
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97Patient follow-up status at the interim analysis
is shown in Figure 1. At time of data lock, less
than one-third of available patients completed the
12-month follow-up; therefore, long-term results will
be reported separately.
BASELINE PATIENT CHARACTERISTICS. Baseline pa-
tient characteristics were not signiﬁcantly different
between the ELA þ PTA and PTA groups. Patients
were predominantly elderly men with claudication
and presented with hypertension, hyperlipidemia,
and smoking history as the most common risk factors.
The percentage of patients previously treated for ISR
was not different between groups (32.7% vs. 30.0%)
(Table 1). Mean lesion length was 19.6  12 cm and
19.3  12 cm in the ELA þ PTA vs. PTA alone groups,
respectively. The majority of lesions were classiﬁed
as TransAtlantic Inter-Society Consensus C/D, and
more than 70% of lesions were >10 cm in length. The
ELA þ PTA group presented with signiﬁcantly higher
frequency of minor stent fractures and with more
extensive calciﬁcation at baseline (Table 2).
EFFICACY OUTCOMES. Procedural success was 93.5%
in the ELA þ PTA group and 82.7% in the PTA
group (p ¼ 0.01). Dissection (7.7% vs. 17.2%; p ¼ 0.03),
bailout stenting (4.1% vs. 11.1%; p ¼ 0.05) and pro-
cedural TLR (5.3% vs. 16.0%; p ¼ 0.008) occurred
signiﬁcantly less frequently in the ELA þ PTA group
compared with the PTA alone group. Distal protection
use and occurrence of embolism were nonsigniﬁ-
cantly higher in the ELA þ PTA group (Table 3).
At 6-month follow-up, 117 of ELA þ PTA and 56 of
PTA patients were available for use in the primary
efﬁcacy endpoint analysis population. Freedom from
TLR was 73.5% versus 51.8%, demonstrating that
ELA þ PTA was superior to PTA alone (p < 0.005)
(Figure 2). ELA þ PTA was also superior to PTA alone
if bailout stenting was not considered a TLR for
the primary efﬁcacy endpoint analysis, 78.1% versus
61.7% (p < 0.05) (Figure 3). ELA þ PTA maintained
superiority in freedom from TLR (p < 0.003) and
patency (p < 0.005) throughout the available follow-
up period (Figures 3 and 4). ELA þ PTA treatment
was also superior to PTA alone for several patient
and lesion groups analyzed by Cox proportional
hazards (Figure 5). Clinical status at 6 months was
similar among both groups; however, patients in
the ELA þ PTA group demonstrated signiﬁcantly
better improvement or maintenance of Rutherford
class (p ¼ 0.008) (Table 4).
SAFETY OUTCOMES. At 30-day follow up, 155 of
ELA þ PTA and 73 of PTA patients were available for
use in the safety analysis. Freedom from any MAEwas 94.2% in the ELA þ PTA group and 79.5% in the
PTA group (p < 0.001), demonstrating that ELA þ PTA
was superior to PTA alone for the primary safety
endpoint. The primary safety endpoint was primarily
driven by TLR; however, 1 PTA patient died within
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9830 days due to hypotensive shock and respiratory
failure.
The ELA þ PTA group maintained superiority in
freedom from an MAE throughout the study period
(Figure 6). TLR was the most common MAE in
both groups. The incidence of major amputation and
mortality through 6 months was low in both groups
(Table 4). There was no change in stent fracture grade
in any patient during the study.
ANALYSIS OF TLR RISK FACTORS. Univariate and
multivariate predictors of TLR are presented in
Table 5. Previous treatment for ISR in the target limb
(hazard ratio [HR]: 1.64, 95% conﬁdence interval
[CI]: 1.06 to 2.54, p ¼ 0.03) and an increased lesion
length (HR: 1.04, 95% CI: 1.02 to 1.05, p < 0.001)
were found to increase the occurrence of TLR,
whereas increased age (HR: 0.77, 95% CI: 0.61 to
0.96, p ¼ 0.02), increased reference vessel diameter
(HR: 0.71, 95% CI: 0.53 to 0.95, p ¼ 0.02) and treat-
ment with ELA þ PTA (HR: 0.48, 95% CI: 0.31 to 0.74,
p ¼ 0.001) were found to decrease the occurrence of
TLR. Lesion length was the only signiﬁcant interac-
tion term identiﬁed. ELA þ PTA performed propor-
tionately better compared with PTA alone in longer
lesions (Figure 7).
DISCUSSION
As the ﬁrst randomized, controlled atherectomy
study of its kind, the EXCITE ISR trial showed thatFIGURE 5 Cox Proportional Hazards Ratio for Subgroups
TLR estimated for subgroups. The diamonds indicate the hazard ratios a
ratio for the indicated covariate subgroup is estimated from a Cox prop
baseline covariate, randomized group, and the interaction between dich
reported is the estimated hazard ratio for the randomized group within
CL ¼ Conﬁdence Limit; ISR ¼ in-stent restenosis; RVD ¼ reference vess
abbreviations as in Table 1.ELA þ PTA reliably achieved superior safety and
efﬁcacy compared with PTA alone. Overall, this
study demonstrated that the beneﬁt-risk proﬁle of
ELA with adjunctive PTA is favorable in the treat-
ment of femoropopliteal ISR, with statistically sig-
niﬁcant reductions in procedural complications,
MAEs, and TLR compared with PTA alone. Freedom
from TLR remained signiﬁcantly better in the ELA þ
PTA group compared with PTA alone when bailout
stenting was not considered a procedural TLR.
Furthermore, there is no evidence of late conver-
gence in either the MAE or TLR survival curves,
suggesting that there is sustained beneﬁt through
12 months.
Excimer laser debulking may be advantageous for
ISR patients because of the ability of this technique
to effectively remove hyperplastic tissue (21). The
predicate device to the Turbo Tandem laser catheter
showed signiﬁcant plaque removal and increased
vessel compliance in de novo lesions of the femo-
ropopliteal artery (22). However, the use of self-
expanding nitinol stents limits positive remodeling
that would otherwise occur in an unconstrained
vessel or in an underexpanded balloon-expandable
stent used in the coronary arteries. Within the stent
lumen, neointimal hyperplasia and extracellular ma-
trix are primary contributors to ISR occurrence and
severity (23). ELA treatment has previously demon-
strated ablation efﬁcacy reducing baseline ISR lesion
stenosis by over 60% (16). The hypothesis that ELAnd the horizontal lines indicate 95% conﬁdence intervals. The hazard
ortional hazards model with independent variables as dichotomous
otomous baseline covariate and randomized group. The hazard ratio
the subgroup obtained from a model using all of the study data.
el diameter; TASC ¼ TransAtlantic Inter-Society Consensus; other
TABLE 5 Cox Proportional Hazards Modelling for Time to
Target Lesion Revascularization
HR 95% CI p Value
Univariate
Target lesion length,
per 1-cm increase
1.03 1.02–1.05 <0.001
Percent diameter stenosis,
per 10% increase
1.25 1.08–1.44 <0.01
Previous treatment for ISR in
target limb, yes/no
1.64 1.08–2.48 0.02
Total occlusion, yes/no 1.57 1.02–2.42 0.04
Age, per 10-yr increase 0.83 0.67–1.02 0.07
Reference vessel diameter,
per 1-mm increase
0.77 0.58–1.02 0.07
Tosaka class (25) 0.07
II vs. I 1.86 0.67–5.18
III vs. I 2.75 0.97–7.81
III vs. II 1.48 0.96–2.29
TASC D lesion, yes/no 1.47 0.93–2.33 <0.10
Multivariate
Target lesion length,
per 1-cm increase
1.04 1.02–1.05 <0.001
Treatment group, ELA þ PTA/PTA 0.48 0.31–0.74 0.001
Reference vessel diameter,
per 1-mm increase
0.71 0.53–0.95 0.02
Age, per 10-yr increase 0.77 0.61–0.96 0.02
Previous treatment for ISR in
target limb, yes/no
1.64 1.06–2.54 0.03
CI ¼ conﬁdence interval; HR ¼ hazard ratio; abbreviations as in Tables 1 and 2.
TABLE 4 6-Month Clinical Outcomes
ELA þ PTA
(n ¼ 169)
PTA
(n ¼ 81) p Value
Primary patency 71.1 56.4 0.004*
Freedom from TLR 79.8 63.7 0.003*
Survival 99.0 95.9 0.14*
Freedom from MAE 79.1 59.5 <0.001*
Freedom from amputation 100 97.7 0.11*
ABI 0.71  0.3 0.77  0.3 0.27
Rutherford class 1.3  1.3 1.5  1.5 0.42
Improved 71.1 65.8 0.008
Same 25.8 15.8
Worsened 3.1 18.4
Values are % or mean  SD. *p value reported at 180-day time point is log-rank
test comparison of survival curves using the Kaplan-Meier product limit method.
MAE ¼ major adverse events; other abbreviations as in Tables 1 and 4.
FIGURE 6 Time to First Major Adverse Event Through 1 Year
Kaplan-Meier survival curve up to 1 year is shown for major adverse events. Number of
subjects at risk is shown at the bottom of the graph (p < 0.001).
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99ISR debulking with adjunctive PTA could reduce TLR
was conﬁrmed in this study.
A covariate analysis for common factors considered
to have an effect on TLR, such as occlusion, diabetes,
sex, and smoking, showed that lesion length, refer-
ence vessel diameter, age, and previous history of ISR
were predictors of TLR. However, lesion length was
found to be the only signiﬁcant interaction term.
Average lesion length in historical ISR reports (PTA
only) ranges from 7 to 20 cm (10,18,24,25). Collec-
tively, lesions in this series were complex, averaging
20 cm in length with over 20% of lesions >30 cm in
length and more than 30% occlusion. A large retro-
spective study on ISR treatment with PTA reported
freedom from TLR at 12 months to be 69% in stenoses
(average length 9 cm) and 23% in long occlusions (25).
In this study, the 6-month freedom from TLR was
53% in the PTA only group, similar to previous studies
in long complex ISR lesions. Overall, ELA þ PTA
reduced the occurrence of TLR by over 50% compared
with PTA alone.
Primary patency remained signiﬁcantly better in
the ELA þ PTA group as compared with PTA alone
throughout the study. Reintervention occurred less
frequently than would be expected by 6-month DUS
examination in both groups. Per protocol, the deci-
sion to undergo reintervention was driven by clinical
symptoms in addition to DUS binary restenosis.
Indeed, recent studies suggest that DUS alone may
not accurately reﬂect ISR stenosis and that the com-
mon threshold for binary restenosis, peak systolic
velocity ratio #2.5, may be inappropriate (26,27).
Clinical surveillance of ISR patients is recommended
to determine the need for reintervention.
Procedural complications were low in both groups.
ELA þ PTA treatment demonstrated signiﬁcantlyfewer procedural major dissections, residual stenosis
>30%, or need for bailout stenting. There were no
new or deteriorated stent fractures due to laser–stent
interaction. Clinically-relevant embolism occurred
FIGURE 7 Lesion Length Interaction
TLR according to lesion length. The diamonds indicate the hazard ratios and the horizontal lines indicate 95% conﬁdence intervals. Values are
considered signiﬁcant (p < 0.05) if the 95% conﬁdence interval does not contain 1. Abbreviations as in Figures 1 and 5.
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100at rates comparable to previous studies in complex
lesions (16,28–30). All events were treated during the
index procedure and resolved without complication.
Paclitaxel drug-coated balloons (DCBs) have shown
superior prevention of restenosis in de novo and ISR
lesions of the femoropopliteal artery compared with
PTA alone (31–34). However, DCB application suffers
from the same procedural complications as PTA,
dissection and residual stenosis necessitating bailout
stenting, occurring in up to 20% of procedures in
de novo and 16% of ISR lesions (24,31,34). As reported
in this study, ELA treatment provides a signiﬁcant
procedural advantage to PTA alone. Therefore, ves-
sel preparation with atherectomy prior to balloon-
dependent drug delivery, especially in the context
of peripheral ISR, may provide interesting research
avenues to reduce procedural complications and
improve drug delivery for long-term results (35–37).
With the eagerly-anticipated approval of DCB in the
United States, larger randomized controlled trials are
needed to test the potential clinical beneﬁts of these
novel combinatorial therapies.
STUDY LIMITATIONS. The study originally planned
to enroll a maximum of 318 randomized patients.
Although the stopping criteria were reached at 250
patients, enabling statistically-powered assessments
of both primary efﬁcacy and safety endpoints, this
study may be underpowered for examining othersecondary variables. The estimated HRs for subgroups
may be prone to inﬂated type I error as these analyses
were not pre-speciﬁed. Conclusive statements would
require validation in a prospectively-designed study
to address the speciﬁc questions. Finally, there was
limited follow-up at 12 months at the time of
data analysis. Long-term data will be reported when
available.
CONCLUSIONS
The EXCITE ISR trial is a ﬁrst-of-its-kind large, pro-
spective, randomized atherectomy study. ELA with
adjunctive balloon angioplasty results in signiﬁcantly
better acute and midterm efﬁcacy and safety out-
comes for treatment of peripheral femoropopliteal
ISR compared with conventional PTA alone in all
lesion types examined in this research.
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